Neuronetics (NASDAQ:STIM) vs. Sintx Technologies (NASDAQ:SINT) Head-To-Head Contrast

Neuronetics (NASDAQ:STIM) and Sintx Technologies (NASDAQ:SINT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.

Profitability

This table compares Neuronetics and Sintx Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Sintx Technologies	-1,058.60%	-366.49%	-115.04%

Analyst Ratings

This is a breakdown of recent ratings for Neuronetics and Sintx Technologies, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1	0	3	0	2.50
Sintx Technologies	1	0	3	0	2.50

Neuronetics presently has a consensus price target of $4.00, suggesting a potential upside of 73.91%. Sintx Technologies has a consensus price target of $9.33, suggesting a potential upside of 462.25%. Given Sintx Technologies’ higher possible upside, analysts plainly believe Sintx Technologies is more favorable than Neuronetics.

Volatility & Risk

Neuronetics has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Sintx Technologies has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Earnings & Valuation

This table compares Neuronetics and Sintx Technologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16 million	1.07	-$39.00 million	($0.54)	-4.26
Sintx Technologies	$1.02 million	7.03	-$10.36 million	($5.07)	-0.33

Sintx Technologies has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 18.4% of Sintx Technologies shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 4.1% of Sintx Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neuronetics beats Sintx Technologies on 8 of the 12 factors compared between the two stocks.

About Neuronetics

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

About Sintx Technologies

Sintx Technologies, Inc., an advanced ceramics company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, technical, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials, polyetheretherketone, and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.